DexCom, Inc.
DXCM
$84.67
-$0.67-0.79%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.04B | 1.11B | 994.20M | 1.00B | 921.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.04B | 1.11B | 994.20M | 1.00B | 921.00M |
| Cost of Revenue | 447.00M | 457.70M | 400.40M | 377.60M | 359.10M |
| Gross Profit | 589.00M | 655.80M | 593.80M | 626.70M | 561.90M |
| SG&A Expenses | 310.10M | 327.40M | 306.40M | 332.70M | 319.30M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 902.30M | 924.60M | 842.20M | 846.30M | 819.90M |
| Operating Income | 133.70M | 188.90M | 152.00M | 158.00M | 101.10M |
| Income Before Tax | 154.30M | 211.30M | 177.40M | 187.80M | 132.50M |
| Income Tax Expenses | 48.90M | 59.60M | 42.80M | 44.30M | -13.90M |
| Earnings from Continuing Operations | 105.40M | 151.70M | 134.60M | 143.50M | 146.40M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 105.40M | 151.70M | 134.60M | 143.50M | 146.40M |
| EBIT | 133.70M | 188.90M | 152.00M | 158.00M | 101.10M |
| EBITDA | 193.70M | 246.70M | 207.30M | 210.10M | 153.60M |
| EPS Basic | 0.27 | 0.39 | 0.34 | 0.36 | 0.38 |
| Normalized Basic EPS | 0.25 | 0.34 | 0.28 | 0.29 | 0.21 |
| EPS Diluted | 0.27 | 0.38 | 0.34 | 0.35 | 0.36 |
| Normalized Diluted EPS | 0.24 | 0.32 | 0.27 | 0.28 | 0.20 |
| Average Basic Shares Outstanding | 391.10M | 390.60M | 394.20M | 399.20M | 390.20M |
| Average Diluted Shares Outstanding | 407.50M | 406.70M | 410.20M | 416.80M | 416.70M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |